3 天之前 · iPSC-derived microglia may help advance ALS research, therapies. Ncardia has launched a stem cell-derived model of human microglia to advance research into …

11 小时之前 · Evaluating masitinib in ALS. A previous Phase 2/3 clinical trial (NCT02588677) tested two daily doses of masitinib (3 or 4.5 mg/kg) against a placebo in nearly 400 adults with …

1 天前 · Ncyte Microglia contains microglia derived from induced pluripotent stem cells (iPSCs). These are created from skin or blood cells of healthy donors or patients and are …

2024年12月30日 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found …

2 天之前 · All four algorithms collectively identified 114 genes representing distinguishing features between ALS and control spinal cord samples. Of these, 41 had been reported to be …

4 天之前 · Results from the studies showed that NP001 did not significantly slow disease progression relative to the placebo, as assessed by the ALS Functional Rating Scale Revised …

2025年1月8日 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an …

New ALS trial data show nearly 2-year survival benefit with NP001. NP001 (sodium chlorite) was associated with a significant survival benefit among a subset of amyotrophic lateral sclerosis …

2024年1月2日 · No. 9 – Further questions set back European approval of AMX0035. Amylyx Pharmaceuticals’ application seeking the approval of AMX0035 in treating ALS patients across …

ALS News Today is a digital platform intended to provide the amyotrophic lateral sclerosis (ALS) community with the most recent news and information on ALS, as well as first-hand …